1474 related articles for article (PubMed ID: 31527380)
1. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
2. Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses.
Ni J; Li G; Yang X; Chu L; Wang J; Li Y; Zou L; Li Y; Xie C; Zhu Z
Radiat Oncol; 2019 Mar; 14(1):44. PubMed ID: 30866974
[TBL] [Abstract][Full Text] [Related]
3. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
[TBL] [Abstract][Full Text] [Related]
4. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
Johung KL; Yeh N; Desai NB; Williams TM; Lautenschlaeger T; Arvold ND; Ning MS; Attia A; Lovly CM; Goldberg S; Beal K; Yu JB; Kavanagh BD; Chiang VL; Camidge DR; Contessa JN
J Clin Oncol; 2016 Jan; 34(2):123-9. PubMed ID: 26438117
[TBL] [Abstract][Full Text] [Related]
5. Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer.
Deng H; Li B; Li L; Peng J; Lv T; Liu Y; Ding C
Pathol Res Pract; 2019 Dec; 215(12):152695. PubMed ID: 31699471
[TBL] [Abstract][Full Text] [Related]
6. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
[TBL] [Abstract][Full Text] [Related]
8. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
9. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S; Zimmermann S
Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
[TBL] [Abstract][Full Text] [Related]
10. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
11. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.
Jamme P; Descarpentries C; Gervais R; Dansin E; Wislez M; Grégoire V; Richard N; Baldacci S; Rabbe N; Kyheng M; Kherrouche Z; Escande F; Copin MC; Cortot AB
Clin Lung Cancer; 2019 Jul; 20(4):297-304.e1. PubMed ID: 31147208
[TBL] [Abstract][Full Text] [Related]
12. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
[TBL] [Abstract][Full Text] [Related]
13. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
Califano R; Greystoke A; Lal R; Thompson J; Popat S
Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer even with brain metastasis.
Muhammet Hacioglu B; Kostek O; Erdogan B; Uzunoglu S; Cicin I
J BUON; 2017; 22(3):586-591. PubMed ID: 28730760
[TBL] [Abstract][Full Text] [Related]
15. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
16. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
17. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
[TBL] [Abstract][Full Text] [Related]
18. Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?
Wrona A
Cancer Radiother; 2019 Sep; 23(5):432-438. PubMed ID: 31331844
[TBL] [Abstract][Full Text] [Related]
19. Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
Jahanzeb M; Lin HM; Pan X; Yin Y; Wu Y; Nordstrom B; Socinski MA
Oncologist; 2020 Oct; 25(10):867-877. PubMed ID: 32490560
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
Kang J; Chen HJ; Zhang XC; Su J; Zhou Q; Tu HY; Wang Z; Wang BC; Zhong WZ; Yang XN; Chen ZH; Ding Y; Wu X; Wang M; Fu JG; Yang Z; Zhang X; Shao YW; Wu YL; Yang JJ
Thorac Cancer; 2018 Sep; 9(9):1093-1103. PubMed ID: 29978950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
